<DOC>
	<DOCNO>NCT02692859</DOCNO>
	<brief_summary>Haemophilus influenza type b ( Hib ) remain serious global health threat associate high mortality morbidity young child . In China , The overall impact Hib-related infection extent coverage Hib conjugate vaccine unclear.Generally , vaccination consider effective way prevent infection Hib.In order evaluate safety immunogenicity haemophilus influenzae type b ( Hib ) conjugate vaccine developped Chengdu Olymvax Biopharmaceuticals Inc. phase III clinical trial plan conduct healthy infant child China .</brief_summary>
	<brief_title>A Phase III Clinical Trial Haemophilus Influenzae Type b ( Hib ) Conjugate Vaccine</brief_title>
	<detailed_description>Haemophilus influenza type b ( Hib ) remain serious global health threat associate high mortality morbidity young child . In China , The overall impact Hib-related infection extent coverage Hib conjugate vaccine unclear.Generally , vaccination consider effective way prevent infection Hib.In order evaluate safety immunogenicity haemophilus influenzae type b ( Hib ) conjugate vaccine developped Chengdu Olymvax Biopharmaceuticals Inc. randomize , positive-controlled , non-inferiority phase III clinical trial plan conduct healthy infant child China .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Haemophilus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy child age 35 months/ 611 months/ 15 age group Without vaccination history Hib conjugate vaccine One his/her guardians able understand sign inform consent Subjects ' guardian comply requirement protocol Subjects temperature &lt; =37.0Â°C axillary setting Subject medical family history following : allergic history , seizure , epilepsy , brain mental disease Subject allergic ingredient vaccine Subject damage low immune function already know Subject Hib disease medical history Subject acute febrile illness infectious disease Major congenital defect , developmental disorder serious chronic illness Thrombocytopenia , blood coagulation disorder bleed difficulty intramuscular injection Subject serious allergic history Subject medical history suitable vaccination difficulty blood collection Any prior administration immunodepressant corticosteroid last 6 month Any prior administration blood product last 3 month Any prior administration research medicine/vaccine last 30 day Any prior administration attenuate live vaccine last 14 day Any prior administration subunit inactivate vaccine last 7 day , pneumococcal vaccine Any medical , psychological , social condition judge investigator , may interfere subject 's compliance protocol his/her guardian 's signature inform consent</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>